Nexavar flunks PhIII adjuvant liver cancer trial
This article was originally published in Scrip
Executive Summary
Bayer/Amgen's hopes of expanding use of their liver cancer drug Nexavar (sorafenib) into a lucrative additional setting look to be thwarted after the Phase III STORM trial, which was launched in 2008, failed to meet its primary endpoint.